You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Monday, Zingernation! You know what they say, “If you can’t beat them, join them.” And that’s why so many retail investors are tailing the trades of Congress members like Nancy Pelosi. And while Marjorie Taylor Greene and Pelosi probably don’t agree on a lot, they’re both buying this cybersecurity stock.

–Aaron Bry & Nic Chahine

Today’s Price Action:

$SPY: +.21%
$QQQ: +.59%
$DIA: +.08%

Plus, you need solid information and quick news to be successful at trading. And now you can get that with Benzinga Pro for 50% off.

TODAY’S MOST VOLATILE STOCKS

TODAY’S TOP STORY

US Banks To Benefit From 'Higher For Longer' Interest Rates: Goldman Sachs Sees 'Modestly Attractive Entry Point' For Investors

What Happened: The emerging scenario of sustained high interest rates could boost the profitability of U.S. banks. That’s according to Goldman Sachs analyst Richard Ramsden who, in a Monday note, expressed cautious optimism for the second-quarter earnings season.

Basically: “In the higher for longer rate environment, long rate-sensitive assets continue to reprice higher, and deposit cost pressure is slowing,” Ramsden wrote.

So: Goldman Sachs anticipates that banks will, on average, report a 7% year-on-year (YoY) revenue growth for the quarter. Trading revenue growth is expected to be a robust segment, projected to average 6% in Q2 2024 and 3% for the year, compared to 2% after fourth quarter 2023 earnings. Here are the other bank stocks that Ramsden likes for the rest of the year.

PRESENTED BY BENZINGA

Get 50% Off Benzinga Pro for July 4th 🇺🇸

For a limited time, you can get the platform trusted by over 6,000 traders, including Wall Street pros, at half the price. Claim your 50% discount.

FIVE MOVERS

Tesla’s stock took off today, closing up more than 5% after the company announced a new energy-storage deal in New Zealand.

Chewy’s stock fell today by more than 6% after Keith Gill aka Roaring Kitty announced a $245 million stake in the company. Here’s why.

Spirit Aerosystem shares closed higher today after Boeing announced a bid to take over the manufacturer for more than $4 billion.

AMD shares closed lower today, as investors appear to be taking profits from the violent semiconductor rally throughout the first half of the year.

Nike’s stock closed higher today as traders bought the dip on the shoe giant after the stock dropped 20% on earnings last week.

ONE TRADE IDEA FOR TOMORROW

EXCLUSIVE: Tesla Delivery Prediction Expert Expects Lower Numbers Than Analysts, Says China 'Not Exactly A Recovery'

Briefly: Electric vehicle leader Tesla Inc is expected to report second-quarter deliveries this week, with estimates seeing a decline on a year-over-year basis from the prior fiscal year.

So: Analysts and Tesla experts are sharing their estimates ahead of the highly anticipated report. Benzinga spoke to one expert on what goes into making accurate estimates.

Making Accurate Tesla Estimates: While many automotive companies report vehicle production and deliveries on a monthly or quarterly basis, there are likely no company figures followed as closely as those of electric vehicle company Tesla. Here’s why one analyst thinks that Tesla’s numbers may be a bit underwhelming.

PRESENTED BY STARPAX

A New Cancer Treatment Conceived To Do What No Other Cancer Treatments Can

Current cancer treatments struggle to reach 90% of the tumor volume. Antibodies, nanocarriers, precision targeting medicine, and even immune cells, don’t reach more than 10% of the tumor volume. Join us in our mission to change the way we treat cancer. 

Here's why you should consider investing in Starpax’s patented technology:

• The future of cancer treatment is here: Starpax's cutting-edge technology features Starpax Living self-propelled Magnetodrones^TM, which are sensitive to special magnetic fields and carry drugs on their surface to the tumor volume. 

• Cutting-edge technology: The Living Magnetodrones, guided by the PolarTrak’s artificial intelligence, are injected directly into the tumor. Preclinical trials have demonstrated a 100% remission rate in extremely aggressive tumors without any side effects observed.

• Reduced risk, accelerated progress: Starpax minimizes trial risks and accelerates approvals with our FDA-approved anti-cancer molecules that can target six common cancers simultaneously. We meet the criteria for the FDA Fast Track Program and Health Canada accelerated review standards.

• Scalable business model: Partnering with top U.S. firms, Starpax plans rapid deployment of 25 treatment centers within seven years, with forecasted EBITDA reaching $12 billion annually upon FDA approval.
  

Invest in Starpax today and be part of this transformative journey.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.